[{"data":1,"prerenderedAt":230},["ShallowReactive",2],{"drug-spironolactone":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":52,"contraindications":124,"warnings":134,"renal":135,"monitoring":136,"interactions":137,"review":138,"examples":141,"atc":156,"iran":158,"links":174,"populations":191,"usApproval":225},"spironolactone",1,{"fa":7,"en":8},"اسپیرونولاکتون","Spironolactone","cardiovascular",{"fa":11,"en":12},"آنتاگونیست آلدوسترون (دیورتیک نگهدارنده پتاسیم)","Aldosterone antagonist (potassium-sparing diuretic)",[14],{"name":15,"market":16},"Aldactone","US",[18,19,7],"aldactone","آلداکتون",[21,35,44],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"tab-25","tablet","oral","25 mg tablet",{"amount":27,"unit":28,"perUnit":23,"scored":29},25,"mg",false,[16],[32],{"source":33,"section":34},"fda-spironolactone","3",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":41,"refs":42},"tab-50","50 mg tablet (scored)",{"amount":39,"unit":28,"perUnit":23,"scored":40},50,true,[16],[43],{"source":33,"section":34},{"id":45,"form":23,"route":24,"label":46,"concentration":47,"markets":49,"refs":50},"tab-100","100 mg tablet (scored)",{"amount":48,"unit":28,"perUnit":23,"scored":40},100,[16],[51],{"source":33,"section":34},[53,77,96,109],{"id":54,"disease":55,"label":56,"population":59,"type":63,"unit":28,"dose":64,"refs":65,"notes":68},"hf","heart-failure",{"fa":57,"en":58},"نارسایی قلبی — ۲۵ mg یک بار در روز","Heart failure — 25 mg once daily",{"minAge":60},{"value":61,"unit":62},18,"year","fixed",{"perDose":27,"dosesPerDay":5},[66],{"source":33,"section":67},"2.2",[69],{"text":70,"refs":73},{"fa":71,"en":72},"اگر پتاسیم ≤۵ و eGFR بالای ۵۰. در صورت تحمل تا ۵۰ mg؛ در هیپرکالمی ۲۵ mg یک روز در میان. eGFR ۳۰ تا ۵۰: شروع یک روز در میان.","If potassium ≤5.0 and eGFR >50. If tolerated up to 50 mg; with hyperkalemia 25 mg every other day. eGFR 30–50: start every other day.",[74,75],{"source":33,"section":67},{"source":33,"section":76},"2",{"id":78,"disease":79,"label":80,"population":83,"type":63,"unit":28,"dose":85,"refs":86,"notes":89},"htn","hypertension",{"fa":81,"en":82},"فشار خون — ۲۵ تا ۱۰۰ mg\u002Fday","Hypertension — 25–100 mg\u002Fday",{"minAge":84},{"value":61,"unit":62},{"perDose":27,"perDoseMax":48,"dosesPerDay":5},[87],{"source":33,"section":88},"2.3",[90],{"text":91,"refs":94},{"fa":92,"en":93},"یک یا چند نوبت؛ بالاتر از ۱۰۰ mg\u002Fday معمولاً اثر بیشتری ندارد.","Single or divided; above 100 mg\u002Fday generally no further benefit.",[95],{"source":33,"section":88},{"id":97,"disease":98,"label":99,"population":102,"type":63,"unit":28,"dose":104,"refs":106},"aldo","hyperaldosteronism",{"fa":100,"en":101},"هیپرآلدوسترونیسم — آمادگی جراحی: ۱۰۰ تا ۴۰۰ mg\u002Fday","Hyperaldosteronism — before surgery: 100–400 mg\u002Fday",{"minAge":103},{"value":61,"unit":62},{"perDose":48,"perDoseMax":105,"dosesPerDay":5},400,[107],{"source":33,"section":108},"2.5",{"id":110,"disease":55,"label":111,"population":114,"type":116,"unit":28,"dose":117,"refs":121},"peds",{"fa":112,"en":113},"زیر ۱۸ سال","Under 18 years",{"maxAge":115},{"value":61,"unit":62},"notCalculated",{"reason":118},{"fa":119,"en":120},"بی‌خطری و اثربخشی در کودکان ثابت نشده است.","Safety and effectiveness in pediatric patients not established.",[122],{"source":33,"section":123},"8.4",[125],{"id":126,"severity":127,"text":128,"refs":131},"ci","block",{"fa":129,"en":130},"هیپرکالمی؛ بیماری آدیسون؛ مصرف همزمان اپلرنون.","Hyperkalemia; Addison's disease; concomitant eplerenone.",[132],{"source":33,"section":133},"4",[],[],[],[],{"status":139,"reviewer":140,"date":140},"unverified",null,[142,147,151],{"regimen":54,"formulation":22,"input":143,"expect":146},{"ageYears":144,"weightKg":145},65,70,{"perDose":27},{"regimen":78,"formulation":22,"input":148,"expect":150},{"ageYears":39,"weightKg":149},80,{"perDose":27,"upperPerDose":48},{"regimen":97,"formulation":45,"input":152,"expect":155},{"ageYears":153,"weightKg":154},45,75,{"perDose":48,"upperPerDose":105},[157],"C03DA01",{"status":159,"forms":160,"refs":169},"registered",[161,165],{"code":162,"en":163,"fa":164},"02099","SPIRONOLACTONE 100MG TAB","قرص اسپیرونولاکتون ۱۰۰ میلی‌گرم",{"code":166,"en":167,"fa":168},"01169","SPIRONOLACTONE 25MG TAB","قرص اسپیرونولاکتون ۲۵ میلی‌گرم",[170],{"source":171,"section":172,"url":173},"darooyab-generic","G-1887\u002FSpironolactone","https:\u002F\u002Fwww.darooyab.ir\u002FG-1887\u002FSpironolactone",[175,179,183,186,189],{"kind":176,"url":177,"label":178},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=202187","ANDA202187",{"kind":180,"url":181,"label":182},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=768563dc-a619-44dc-b97f-1a7e71fd56a0","FDA Spironolactone",{"kind":184,"url":185,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa682627.html",{"kind":187,"url":188,"label":157},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=C03DA01",{"kind":190,"url":173,"label":8},"darooyab",{"pregnancy":192,"lactation":201,"pediatric":209,"geriatric":217},{"level":193,"text":194,"quote":197,"refs":198},"caution",{"fa":195,"en":196},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary Based on mechanism of action and findings in animal studies, spironolactone may affect sex differentiation of the male during embryogenesis (see Data).",[199],{"source":33,"section":200},"8.1",{"level":193,"text":202,"quote":205,"refs":206},{"fa":203,"en":204},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary Spironolactone is not present in breastmilk; however, limited data from a lactating woman at 17 days postpartum reports the presence of the active metabolite, canrenone, in human breast milk in low amounts that are expected to be clinically inconsequential.",[207],{"source":33,"section":208},"8.2",{"level":210,"text":211,"quote":214,"refs":215},"not-established",{"fa":212,"en":213},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness in pediatric patients have not been established.",[216],{"source":33,"section":123},{"level":193,"text":218,"quote":221,"refs":222},{"fa":219,"en":220},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","Because elderly patients are more likely to have decreased renal function, monitor renal function.",[223],{"source":33,"section":224},"8.5",{"kind":226,"refs":227,"id":178},"ANDA",[228],{"source":33,"section":229},"SPL approval \u002F marketing category",1792191869824]